Caring for patients with acute myeloid leukemia (AML) depends on many factors and can vary as much as the patients themselves.
Caring for patients with acute myeloid leukemia (AML) depends on many factors and can vary as much as the patients themselves. As such, shared decision-making—those collaborative conversations between patient and physician that guide the treatment trajectory—are critical to align goals and help determine what’s best for each patient.
Due to the challenges COVID-19 presents for immune-compromised individuals, clinicians are having more complex discussions with their patients diagnosed with AML—including how to proceed with the COVID-19 vaccine and booster shot.
Guests:
Jonathan Abbas, MD
Director of Acute Leukemia Program
Tennessee Oncology
Ehab Atallah, MD
Professor of Medicine and Section Head of Hematological Malignancies
Medical College of Wisconsin
Catherine Lai, MD, MPH
Director of Leukemia
Georgetown University Medical Center
“Treatment for AML, acute myeloid leukemia, is extremely personal. Depending on the age of the patient, their comorbidities, and their geography, and their family support, and their wishes – there are all levels of intensity of treatment. …So, when you meet a new patient with AML, the first thing you have to do is decide what is the goal for the patient and the goal for the family. And of course, this in the times of COVID, becomes even more challenging.” - Jonathan Abbas, MD
Podcasts:
Webinars:
Publications:
This podcast is produced as part of the “Returning to Practice in the Post-COVID-19 Era: Hematology Disease Education” program.
February 19, 2026
January 30, 2026
January 21, 2026
